Hodgkin lymphoma is a rare B-cell malignant neoplasm affecting approximately 9000 new
patients annually. This disease represents approximately 11% of all lymphomas seen in the …

Abstract Disease Overview Hodgkin lymphoma (HL) is an uncommon B‐cell lymphoid
malignancy affecting 8500 new patients annually and representing approximately 10.2% of …

Abstract The European Group for Blood and Marrow Transplantation regularly publishes
special reports on the current practice of haematopoietic SCT for haematological diseases …

We compared the outcome of nonmyeloablative allogeneic hematopoietic cell
transplantation (HCT) for patients with relapsed or refractory Hodgkin lymphoma (HL) based …

Abstract Background and Objectives Response to pre-transplant salvage chemotherapy
remains the most important prognostic factor for outcome in refractory or relapsed Hodgkin's …

Autologous hematopoietic stem cell transplantation (ASCT) has become standard therapy
for primary refractory (PR REF) or relapsed (REL) Hodgkin's lymphoma (HL); however, more …

Twenty-six patients with advanced Hodgkin's disease received a related HLA haploidentical
unmanipulated BMT, following a non-myeloablative conditioning with low-dose TBI …

To determine prognostic factors and treatment outcome, patients with primary progressive
Hodgkin lymphoma (HD) registered in the database of the German Hodgkin Lymphoma …

Disease overview: Hodgkin lymphoma (HL) is an uncommon B‐cell lymphoid malignancy
affecting 9,050 new patients annually and representing approximately 11.2% of all …

Relapsed or refractory Hodgkin lymphoma is a challenging problem for clinicians who treat
hematologic malignancies. The standard management of these patients should include the …